Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Similar documents
Solid Organ Transplant Benefits to Change for Texas Medicaid

Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Cardiac Rehabilitation Services

APPENDIX A Certification of Advanced Disease:

High Performance Network Quality Criteria for Designation

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP

Ontario s Referral and Listing Criteria for Adult Heart Transplantation

Obesity/Morbid Obesity/BMI

Corporate Governance Code for Funds: What Will it Mean?

CLINICAL MEDICAL POLICY

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Important Information

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

Influenza (Flu) Fact Sheet

Related Policies None

Significance of Chronic Kidney Disease in 2015

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

COPD Care. Course Handouts & Post Test. COPD Care. Objectives: o To download presentation handouts, click on the attachment icon

Risk factors in health and disease

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

US Public Health Service Clinical Practice Guidelines for PrEP

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

2017 CMS Web Interface

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Widening of funding restrictions for rituximab and eltrombopag

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

How to become an AME Online

Osteoporosis Fast Facts

DRAFT Policy for the Management of Ear Wax

Commissioning Policy: South Warwickshire CCG (SWCCG)

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745

2017 CMS Web Interface

Summary of Significant Changes. Policy

Emergency Department Performance Measures

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

2018 CMS Web Interface

2017 CMS Web Interface

HIP REPLACEMENT SURGERY (ARTHROPLASTY)

2018 CMS Web Interface

Donating a Kidney for Transplantation. Living Kidney Donation Patient Education

Drug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

LTCH QUALITY REPORTING PROGRAM

Methadone Maintenance Treatment for Opioid Dependence

BANKMED MEDICAL SCHEME. MEDICINE ADVISORY SERVICES (Chronic Medicine Benefit) GENERAL INFORMATION

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

PROVIDER ALERT. Comprehensive Diagnostic Evaluation (CDE) Guidelines to Access the Applied Behavior Analysis (ABA) Benefit.

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Clinical Policy Title: Lung transplants

CONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW

Diagnosis and Management of COPD Clinical Practice Guideline. MedStar Health

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC)

Adult Preventive Care Guidelines

S.K.J Construction Ltd Groundwork & Civil Engineering

Immunisation and Disease Prevention Policy

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Annex III. Amendments to relevant sections of the Product Information

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17

Folotyn (pralatrexate)

International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma 1

Nova Scotia Guidelines for Acute Coronary Syndromes (2008) QUICK REFERENCE MARCH Supported by unrestricted educational grants from:

Ministry of Health and Long-Term Care

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.

Bedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:

FUNCTIONAL MOVEMENT SYSTEMS SCREEN FINDINGS REPORT

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

A foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:

COPD Outreach Program

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

<Date> <Group> <Address1> <Address2> <City> <State> <zip> RE: 2015 Blue Physician Recognition (BPR) Program. Dear <Group>:

ICD-10-CM Coding Basics Chapter Specifics

Through our exceptional health care services, we reveal the healing presence of God.

Through our exceptional health care services, we reveal the healing presence of God.

2017 CMS Web Interface

CDC Influenza Division Key Points November 7, 2014

Page 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided

Completing the NPA online Patient Safety Incident Report form: 2016

Factors Associated with Opioid-Related Fatal and Non-fatal Overdose

Guidelines for the Admission of Children and Young People with an Eating Disorder

WHAT IS HEAD AND NECK CANCER FACT SHEET

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals

2018 CMS Web Interface

Policy. Medical Policy Manual Approved: Do Not Implement Until 1/1/18. Applied Behavioral Analysis (ABA)

The Four Links of Obesity: Diabetes, Fatty Liver, Cardiomyopathy and AF The Potential Benefit and Rapid Evolution of Bariatric Surgery

Annual Principal Investigator Worksheet About Local Context

HEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8

Reliability and Validity Plan 2017

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Clinical Study Synopsis

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

Transcription:

Ontari s Referral and Listing Criteria fr Adult Lung Transplantatin Versin 2.0 Trillium Gift f Life Netwrk

Adult Lung Transplantatin Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient referral criteria are guidelines which a Health Care Prvider wuld utilize t refer a patient t a transplant center fr assessment. In general, referral fr lung transplantatin assessment is advisable when patients have a less than 50%, 2- t 3-year predicted survival r New Yrk Heart Assciatin (NYHA) class III r IV level f functin, r bth. The criteria identified belw are the agreed upn cnditins fr which a patient shuld be referred fr lung transplant assessment. 1) Chrnic Obstructive Pulmnary Disease (COPD): Referral fr lung transplantatin shuld be cnsidered fr patients with a Bdy-Mass Index, Airflw Obstructin, Dyspnea, and Exercise (BODE) index scre f greater than 5. 2) Cystic Fibrsis and Other Causes f Brnchiectasis: Referral fr lung transplantatin shuld be cnsidered fr patients with cystic fibrsis and ther causes f brnchiectasis. Such patients wuld have ne r mre f the fllwing: Frced Expiratry Vlume (FEV1) belw 30% predicted r a rapid decline in FEV1, especially in yung female patients; Exacerbatin f pulmnary disease requiring ICU stay; Increasing frequency f exacerbatins requiring antibitic therapy; Refractry and/r recurrent pneumthrax; r Recurrent hemptysis nt cntrlled by emblizatin. 3) Idipathic Pulmnary Fibrsis and Nn-Specific Interstitial Pneumnia: Referral fr lung transplantatin shuld be cnsidered fr patients with histlgic r radigraphic evidence f Usual Interstitial Pneumnia (UIP) irrespective f vital capacity. Patients with histlgic evidence f fibrtic Nn-Specific Interstitial Pneumnia (NSIP) may als be referred fr lung transplant assessment. 4) Pulmnary Arterial Hypertensin: Patients with a New Yrk Heart Assciatin (NYHA) functinal class f III r IV, irrespective f nging therapy and rapidly prgressive disease, may be referred fr lung transplant assessment. 5) Sarcidsis: Referral fr lung transplantatin shuld be cnsidered fr patients with sarcidsis if they are NYHA functinal class III r IV. 6) Lymphangilei-mymatsis: Referral fr lung transplantatin shuld be cnsidered fr patients with lymphangilei-mymatsis if they are NYHA functinal class III r IV. 7) Pulmnary Langerhans Cell Histicytsis (Esinphilic Granulma): Referral fr lung transplantatin shuld be cnsidered fr patients with pulmnary Langerhans cell histicytsis if they are NYHA functinal class III r IV. 2

PATIENT LISTING INDICATIONS: Each patient is assessed individually fr their suitability fr transplantatin by the transplant prgram. The criteria identified belw are the cnditins fr which a patient may be eligible t be waitlisted fr lung transplantatin in Ontari. 1) Chrnic Obstructive Pulmnary Disease (COPD): Listing fr lung transplantatin may be cnsidered fr patients with COPD. Such patients wuld meet the fllwing criteria: Bdy-Mass Index, Airflw Obstructin, Dyspnea, and Exercise (BODE) capacity index f 7-10, r at least ne f the fllwing: Histry f hspitalizatin fr exacerbatin assciated with acute hypercapnia (PCO 2 exceeding 50 mm Hg); Pulmnary hypertensin r cr pulmnale, r bth, despite xygen therapy; r, Frced Expiratry Vlume (FEV1) f less than 20% and either Carbn Mnxide Diffusing Capacity (DLCO) f less than 20% r hmgenus distributin f emphysema. 2) Cystic Fibrsis and Other Causes f Brnchiectasis: Listing fr lung transplantatin may be cnsidered fr patients with cystic fibrsis r ther causes f brnchiectasis. Such patients wuld have ne f the fllwing: Oxygen-dependent respiratry failure; Hypercapnia; r, Pulmnary hypertensin. 3) Idipathic Pulmnary Fibrsis and Nn-Specific Interstitial Pneumnia: Listing fr lung transplantatin may be cnsidered fr patients with idipathic pulmnary fibrsis r nn-specific interstitial pneumnia. Such patients wuld have: Histlgic r radigraphic evidence f UIP and any f the fllwing: A DLCO f less than 39% predicted; A 10% r greater decrement in frced vital capacity (FVC) during 6 mnths f fllw-up; A decrease in pulse ximetry belw 88% during a 6-Minute Walk Test (MWT); r, Hneycmbing n High Reslutin Cmputed Tmgraphy (HRCT) (fibrsis scre f >2). Histlgic evidence f NSIP and any f the fllwing: A DLCO f less than 35% predicted; r, A 10% r greater decrement in FVC r 15% decrease in DLCO during 6 mnths f fllwup. 4) Pulmnary Arterial Hypertensin: Listing fr lung transplantatin may be cnsidered fr patients with pulmnary arterial hypertensin. Such patients wuld have ne f the fllwing: Persistent NYHA class III r IV n maximal medical therapy; Lw r declining 6-MWT; Failing therapy with intravenus epprstenl, r equivalent; Cardiac index f less than 2 liters/min/m 2 ; r, Right atrial pressure exceeding 15 mm Hg. 5) Sarcidsis: Listing fr lung transplantatin may be cnsidered fr patients with sarcidsis. Such patients wuld meet the fllwing criteria: Impairment f exercise tlerance (NYHA functinal class III r IV) and any f the fllwing: Hypxemia at rest; Pulmnary hypertensin; r, Elevated right atrial pressure exceeding 15 mm Hg. 3

6) Lymphangilei-mymatsis: Patients with lymphangilei-mymatsis may be cnsidered fr lung transplantatin. Such patients wuld have ne f the fllwing: Severe impairment in lung functin and exercise capacity (e.g., VO 2 max < 50% predicted); r, Hypxemia at rest. 7) Pulmnary Langerhans Cell Histicytsis (Esinphilic Granulma): Patients with pulmnary langerhans cell histicytsis may be cnsidered fr lung transplantatin. Such patients wuld have ne f the fllwing: Severe impairment in lung functin and exercise capacity; r, Hypxemia at rest. 8) General: Patients nt included in the preceding categries but have a pr quality f life (based n the clinical judgment f the care team at the time f assessment) may be cnsidered fr lung transplantatin. ABSOLUTE LISTING CONTRAINDICATIONS: The fllwing are cnditins relating t the lung transplant candidate that cnstitute abslute cntraindicatins t lung transplantatin. As such, they prevent a transplant frm being dne until the cnditin is reslved. 1) Psychscial Issues: Patients must underg a cmplete psychscial evaluatin prir t listing fr transplant. Patients wh display the fllwing are nt candidates fr lung transplantatin: Dcumented nn-adherence r inability t fllw thrugh with medical therapy r ffice fllw-up, r bth; Untreatable psychiatric r psychlgic cnditin assciated with the inability t cperate r cmply with medical therapy; Absence f a cnsistent r reliable scial supprt system; r, Active alchl r ther substance misuse within last 6 mnths. RELATIVE LISTING CONTRAINDICATIONS: The fllwing are cnditins relating t the lung transplant candidate that cnstitute relative cntraindicatins t lung transplantatin. While each patient is evaluated n an individual basis, the presence f ne r mre f the fllwing may preclude a candidate frm being listed n the lung transplantatin wait list. 1) Age: Patients lder than 65 years may nt be eligible fr lung transplantatin. Older patients have less ptimal survival, likely due t cmrbidities, and therefre recipient age shuld be a factr in candidate selectin. Althugh there cannt be endrsement f an upper age limit as an abslute cntraindicatin, the presence f several relative cntraindicatins can cmbine t increase the risks f transplantatin abve a safe threshld. 2) Medical Stability: Patients with critical r unstable clinical cnditins (e.g., shck, mechanical ventilatin r extra-crpreal membrane xygenatin) may nt be eligible fr lung transplantatin. 3) Functinal Status: Patients with severely limited functinal status with pr rehabilitatin ptential may nt be eligible fr lung transplantatin. 4) Infectin: Patients with clnized and highly resistant r highly virulent bacteria, fungi, r mycbacteria infectin may nt be eligible fr lung transplantatin. Patients with nn-curable chrnic extrapulmnary 4

infectin including chrnic active viral hepatitis B, hepatitis C, and human immundeficiency virus may nt be eligible fr lung transplantatin. 5) Obesity: Patients with severe besity defined as a bdy mass index (BMI) exceeding 30 kg/m 2 may nt be eligible fr lung transplantatin. 6) Osteprsis: Patients with severe r symptmatic steprsis may nt be eligible fr lung transplantatin. 7) Mechanical Ventilatin: Patients with mechanical ventilatin may nt be eligible fr lung transplantatin. Hwever, carefully selected candidates n mechanical ventilatin withut ther acute r chrnic rgan dysfunctin, wh are able t actively participate in a meaningful rehabilitatin prgram, may be successfully transplanted. 8) Disease: Patients with untreatable advanced dysfunctin f anther majr rgan system (e.g. heart, liver, r kidney) may nt be eligible fr lung transplantatin. Crnary artery disease nt amenable t percutaneus interventin r bypass grafting, r assciated with significant impairment f left ventricular functin, is an abslute cntraindicatin t lung transplantatin, but heart-lung transplantatin culd be cnsidered in highly selected cases. Other medical cnditins that have nt resulted in end-stage rgan damage, such as diabetes mellitus, systemic hypertensin, peptic ulcer disease, r gastresphageal reflux shuld be ptimally treated befre transplantatin. Patients with crnary artery disease may underg percutaneus interventin befre transplantatin r crnary artery bypass grafting cncurrent with the prcedure. 9) Malignancy: Patients with malignancy in the last 2 years, with the exceptin f cutaneus squamus and basal cell tumrs, may nt be eligible fr lung transplantatin. In general, a 5-year disease-free interval is prudent. The rle f lung transplantatin fr lcalized brnchialvelar cell carcinma remains cntrversial. 10) Defrmity: Patients with significant chest wall/spinal defrmity may nt be eligible fr lung transplantatin. 5

Versin Cntrl: Name f Dcument Ontari s Referral and Listing Criteria fr Lung Transplantatin Versin 1.0 Created May 2011 Versin 2.0 Updated February 2015 Recmmended Next Review February 2017 Apprved By Prvincial Heart and Lung Wrking Grup Transplant Steering Cmmittee 6